SE465109B - Antibakteriell komposition - Google Patents

Antibakteriell komposition

Info

Publication number: SE465109B
Authority: SE; Sweden
Prior art keywords: casein; milk; pneumoniae; influenzae; fraction
Prior art date: 1989-10-30

Application number

SE8903625A

Other languages

English (en)

Swedish (sv)

Other versions

SE8903625D0 (sv

SE8903625L (sv

Inventor

Bengt Andersson

Catharina Svanborg Eden

Gustav Aniansson

Ragnar Lindstedt

Original Assignee

Bengt Andersson

Catharina Svanborg Eden

Gustav Aniansson

Ragnar Lindstedt

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-10-30

Filing date

1989-10-30

Publication date

1991-07-29

1989-10-30 Application filed by Bengt Andersson, Catharina Svanborg Eden, Gustav Aniansson, Ragnar Lindstedt filed Critical Bengt Andersson

1989-10-30 Priority to SE8903625A priority Critical patent/SE465109B/sv

1989-10-30 Publication of SE8903625D0 publication Critical patent/SE8903625D0/xx

1990-10-30 Priority to DK90916537T priority patent/DK0454813T3/da

1990-10-30 Priority to DE69032646T priority patent/DE69032646T2/de

1990-10-30 Priority to ES90916537T priority patent/ES2121755T3/es

1990-10-30 Priority to HU912203A priority patent/HU212935B/hu

1990-10-30 Priority to CA002044244A priority patent/CA2044244A1/en

1990-10-30 Priority to PCT/SE1990/000702 priority patent/WO1991006308A1/en

1990-10-30 Priority to KR1019910700615A priority patent/KR920700678A/ko

1990-10-30 Priority to EP90916537A priority patent/EP0454813B1/de

1990-10-30 Priority to AT90916537T priority patent/ATE170754T1/de

1990-10-30 Priority to AU66470/90A priority patent/AU633647B2/en

1990-10-30 Priority to JP2515465A priority patent/JPH04503077A/ja

1991-05-01 Publication of SE8903625L publication Critical patent/SE8903625L/

1991-06-19 Priority to NO912391A priority patent/NO912391D0/no

1991-06-28 Priority to FI913154A priority patent/FI102516B1/fi

1991-06-28 Priority to SU914895868A priority patent/RU2035913C1/ru

1991-07-29 Publication of SE465109B publication Critical patent/SE465109B/sv

1997-06-20 Priority to US08/880,132 priority patent/US5968901A/en

Links

230000000844 anti-bacterial effect Effects 0.000 title claims description 9
239000000203 mixture Substances 0.000 title abstract description 7
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 53
235000021240 caseins Nutrition 0.000 claims abstract description 53
239000005018 casein Substances 0.000 claims abstract description 50
235000013336 milk Nutrition 0.000 claims abstract description 28
210000004080 milk Anatomy 0.000 claims abstract description 28
239000008267 milk Substances 0.000 claims abstract description 27
235000020256 human milk Nutrition 0.000 claims abstract description 23
210000004251 human milk Anatomy 0.000 claims abstract description 23
238000002360 preparation method Methods 0.000 claims abstract description 8
230000001225 therapeutic effect Effects 0.000 claims abstract description 8
208000015181 infectious disease Diseases 0.000 claims abstract description 6
230000000069 prophylactic effect Effects 0.000 claims abstract description 3
239000000758 substrate Substances 0.000 claims abstract description 3
241000283690 Bos taurus Species 0.000 claims description 19
210000003022 colostrum Anatomy 0.000 claims description 6
235000021277 colostrum Nutrition 0.000 claims description 6
235000013305 food Nutrition 0.000 claims description 5
238000011321 prophylaxis Methods 0.000 claims description 5
206010057190 Respiratory tract infections Diseases 0.000 claims 3
239000008194 pharmaceutical composition Substances 0.000 claims 2
208000020029 respiratory tract infectious disease Diseases 0.000 claims 2
235000020183 skimmed milk Nutrition 0.000 claims 1
241000894006 Bacteria Species 0.000 abstract description 20
241000606768 Haemophilus influenzae Species 0.000 abstract description 6
210000002345 respiratory system Anatomy 0.000 abstract description 4
238000011282 treatment Methods 0.000 abstract description 3
102000011632 Caseins Human genes 0.000 description 52
108010076119 Caseins Proteins 0.000 description 52
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
108010046377 Whey Proteins Proteins 0.000 description 14
235000002639 sodium chloride Nutrition 0.000 description 14
239000011780 sodium chloride Substances 0.000 description 14
230000005764 inhibitory process Effects 0.000 description 13
230000002401 inhibitory effect Effects 0.000 description 12
239000005862 Whey Substances 0.000 description 11
102000007544 Whey Proteins Human genes 0.000 description 11
230000000694 effects Effects 0.000 description 9
210000004027 cell Anatomy 0.000 description 8
238000005119 centrifugation Methods 0.000 description 8
229920001542 oligosaccharide Polymers 0.000 description 8
150000002482 oligosaccharides Chemical class 0.000 description 8
210000002919 epithelial cell Anatomy 0.000 description 7
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
239000003112 inhibitor Substances 0.000 description 6
238000000034 method Methods 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
239000000243 solution Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
230000001580 bacterial effect Effects 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
241000894007 species Species 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229940021722 caseins Drugs 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000002609 medium Substances 0.000 description 3
210000001989 nasopharynx Anatomy 0.000 description 3
239000012074 organic phase Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
235000021119 whey protein Nutrition 0.000 description 3
235000021246 κ-casein Nutrition 0.000 description 3
229920001817 Agar Polymers 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
208000005141 Otitis Diseases 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000001070 adhesive effect Effects 0.000 description 2
239000008272 agar Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
229960001231 choline Drugs 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
208000019258 ear infection Diseases 0.000 description 2
239000000945 filler Substances 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
BPSNETAIJADFTO-UHFFFAOYSA-N 2-pyridinylacetic acid Chemical compound OC(=O)CC1=CC=CC=N1 BPSNETAIJADFTO-UHFFFAOYSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229920000945 Amylopectin Polymers 0.000 description 1
108010037833 Bacterial Adhesins Proteins 0.000 description 1
101000946377 Bos taurus Alpha-lactalbumin Proteins 0.000 description 1
101000798100 Bos taurus Lactotransferrin Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
241000700198 Cavia Species 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
108090000746 Chymosin Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
101710146739 Enterotoxin Proteins 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
229920003139 Eudragit® L 100 Polymers 0.000 description 1
229920003141 Eudragit® S 100 Polymers 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108010015899 Glycopeptides Proteins 0.000 description 1
102000002068 Glycopeptides Human genes 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000946384 Homo sapiens Alpha-lactalbumin Proteins 0.000 description 1
101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000004407 Lactalbumin Human genes 0.000 description 1
108090000942 Lactalbumin Proteins 0.000 description 1
102000010445 Lactoferrin Human genes 0.000 description 1
108010063045 Lactoferrin Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
206010028735 Nasal congestion Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
241000700605 Viruses Species 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
229920006318 anionic polymer Polymers 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
239000003831 antifriction material Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
235000008452 baby food Nutrition 0.000 description 1
239000011324 bead Substances 0.000 description 1
239000006161 blood agar Substances 0.000 description 1
229940072440 bovine lactoferrin Drugs 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
235000013351 cheese Nutrition 0.000 description 1
238000000546 chi-square test Methods 0.000 description 1
229940080701 chymosin Drugs 0.000 description 1
239000004927 clay Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
IRXRGVFLQOSHOH-UHFFFAOYSA-L dipotassium;oxalate Chemical compound [K+].[K+].[O-]C(=O)C([O-])=O IRXRGVFLQOSHOH-UHFFFAOYSA-L 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000147 enterotoxin Substances 0.000 description 1
231100000655 enterotoxin Toxicity 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
235000013861 fat-free Nutrition 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
230000035931 haemagglutination Effects 0.000 description 1
239000006466 haemophilus medium Substances 0.000 description 1
102000050459 human LTF Human genes 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
-1 ka- sein Proteins 0.000 description 1
CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
235000021242 lactoferrin Nutrition 0.000 description 1
229940078795 lactoferrin Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
150000002597 lactoses Chemical class 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
235000013384 milk substitute Nutrition 0.000 description 1
239000003595 mist Substances 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 description 1
RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
210000003300 oropharynx Anatomy 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
235000021395 porridge Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
239000001993 wax Substances 0.000 description 1
235000008939 whole milk Nutrition 0.000 description 1
235000021249 α-casein Nutrition 0.000 description 1
235000021241 α-lactalbumin Nutrition 0.000 description 1
235000021247 β-casein Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
- A23J1/202—Casein or caseinates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4732—Casein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Virology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Polymers & Plastics (AREA)
Pulmonology (AREA)
Food Science & Technology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)

SE8903625A 1989-10-30 1989-10-30 Antibakteriell komposition SE465109B (sv)

Priority Applications (16)

Application Number	Priority Date	Filing Date	Title
SE8903625A SE465109B (sv)	1989-10-30	1989-10-30	Antibakteriell komposition
JP2515465A JPH04503077A (ja)	1989-10-30	1990-10-30	抗菌組成物
EP90916537A EP0454813B1 (de)	1989-10-30	1990-10-30	Eine caseinfraktion zur therapeutischen vorbeugenden und/oder diagnostischen verwendung bei atemweginfektionen
AU66470/90A AU633647B2 (en)	1989-10-30	1990-10-30	A casein fraction for therapeutic, profylactic and/or diagnostic use in infections of the respiratory tract
ES90916537T ES2121755T3 (es)	1989-10-30	1990-10-30	Fraccion de caseina para uso terapeutico, profilactico y/o diagnostico en infecciones del tracto respiratorio.
HU912203A HU212935B (en)	1989-10-30	1990-10-30	Process for producing pharmaceutical compositions, medicinal human aliments and animal food containing casein
CA002044244A CA2044244A1 (en)	1989-10-30	1990-10-30	Antibacterial composition
PCT/SE1990/000702 WO1991006308A1 (en)	1989-10-30	1990-10-30	A casein fraction for therapeutic, profylactic and/or diagnostic use in infections of the respiratory tract
KR1019910700615A KR920700678A (ko)	1989-10-30	1990-10-30	항-박테리아 성분물
DK90916537T DK0454813T3 (da)	1989-10-30	1990-10-30	Caseinfraktion til terapeutisk, profylaktisk og/eller diagnostisk anvendelse ved infektioner i åndedrætssystemet
AT90916537T ATE170754T1 (de)	1989-10-30	1990-10-30	Eine caseinfraktion zur therapeutischen vorbeugenden und/oder diagnostischen verwendung bei atemweginfektionen
DE69032646T DE69032646T2 (de)	1989-10-30	1990-10-30	Eine caseinfraktion zur therapeutischen vorbeugenden und/oder diagnostischen verwendung bei atemweginfektionen
NO912391A NO912391D0 (no)	1989-10-30	1991-06-19	Kaseinfraksjon for terapeutisk, profylaktisk og/eller diagnostisk anvendelse paa infeksjoner i aandedrettsorganene.
FI913154A FI102516B1 (fi)	1989-10-30	1991-06-28	Menetelmä kaseiinifraktion valmistamiseksi, jolla on kiinnittymistä estävä vaikutus bakteereihin
SU914895868A RU2035913C1 (ru)	1989-10-30	1991-06-28	Средство, ингибирующее связывание s.pneumoniae и/или h. influenzae, и композиция, содержащая это средство
US08/880,132 US5968901A (en)	1989-10-30	1997-06-20	Antibacterial composition

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE8903625A SE465109B (sv)	1989-10-30	1989-10-30	Antibakteriell komposition

Publications (3)

Publication Number	Publication Date
SE8903625D0 SE8903625D0 (sv)	1989-10-30
SE8903625L SE8903625L (sv)	1991-05-01
SE465109B true SE465109B (sv)	1991-07-29

Family

ID=20377332

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE8903625A SE465109B (sv)	1989-10-30	1989-10-30	Antibakteriell komposition

Country Status (15)

Country	Link
EP (1)	EP0454813B1 (de)
JP (1)	JPH04503077A (de)
KR (1)	KR920700678A (de)
AT (1)	ATE170754T1 (de)
AU (1)	AU633647B2 (de)
CA (1)	CA2044244A1 (de)
DE (1)	DE69032646T2 (de)
DK (1)	DK0454813T3 (de)
ES (1)	ES2121755T3 (de)
FI (1)	FI102516B1 (de)
HU (1)	HU212935B (de)
NO (1)	NO912391D0 (de)
RU (1)	RU2035913C1 (de)
SE (1)	SE465109B (de)
WO (1)	WO1991006308A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995032728A1 (en) *	1994-05-26	1995-12-07	Abbott Laboratories	Inhibition of attachment of h. influenzae to human cells
US5506209A (en) *	1994-05-26	1996-04-09	Abbott Laboratories	Product for inhibition of infection of mammalian cells by respiratory syncytial virus
US5707968A (en) *	1994-05-26	1998-01-13	Abbott Laboratories	Inhibition of attachment of H.influenzae to human cells
US5538952A (en) *	1994-05-26	1996-07-23	Abbott Laboratories	Inhibition of infection of mammalian cells by respiratory syncytial virus
NZ283578A (en) *	1994-05-26	1998-05-27	Abbott Lab	Nutritional product containing beta casein effective in preventing infection of human cells by respiratory syncytial virus
US5643880A (en) *	1994-05-26	1997-07-01	Abbott Laboratories	Product for inhibition of attachment of H. influenzae to human cells
US5942254A (en) *	1995-02-27	1999-08-24	Abbott Laboratories	Phosphorylated recombinant human β-casein expressed in a bacterial system
CA2234680A1 (en) *	1995-11-06	1997-07-24	Abbott Laboratories	Product for inhibition of attachment of h. influenzae to human cells
JP2000500141A (ja) *	1995-11-06	2000-01-11	アボツト・ラボラトリーズ	リン酸化された組換えヒトベータ−カゼインを用いるヒト細胞に対するインフルエンザ菌の付着阻止方法
AUPP494798A0 (en)	1998-07-29	1998-08-20	Pacific Biolink Pty Limited	Protective protein formulation
RU2346694C2 (ru) *	2002-11-26	2009-02-20	Дзе Юниверсити Оф Чикаго	Вещества и способы для профилактики и лечения опосредованных микроорганизмами эпителиальных нарушений
JP5271475B2 (ja)	2002-11-26	2013-08-21	ザユニヴァーシティーオヴシカゴ	微生物媒介上皮疾患の予防及び治療のための材料並びに方法
MX2010000333A (es) *	2007-07-06	2010-03-30	Laclede Inc	Uso de enzimas hidroliticas y oxidativas para disolver la biopelicula en pasajes de vias aereas.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1496671A (en) *	1975-03-27	1977-12-30	Grindstedvaerket As	Anti-cancer-active sour milk fraction
FR2491334A1 (fr) *	1980-10-03	1982-04-09	Inst Nat Sante Rech Med	Nouvelles substances biologiquement actives, leur obtention a partir de caseine humaine et compositions les contenant
FR2592769B1 (fr) *	1986-01-10	1990-10-12	Agronomique Inst Nat Rech	Procede d'obtention d'une matiere enrichie en caseine beta, appareillage pour la mise en oeuvre de ce procede, et application des produits obtenus par ce procede comme aliments, complements alimentaires ou additifs en industrie alimentaire et pharmaceutique ou dans la preparation de peptides a activite physiologique
JP2631470B2 (ja) *	1987-05-15	1997-07-16	雪印乳業株式会社	感染防御剤

1989
- 1989-10-30 SE SE8903625A patent/SE465109B/sv not_active IP Right Cessation
1990
- 1990-10-30 AU AU66470/90A patent/AU633647B2/en not_active Ceased
- 1990-10-30 DE DE69032646T patent/DE69032646T2/de not_active Expired - Fee Related
- 1990-10-30 HU HU912203A patent/HU212935B/hu not_active IP Right Cessation
- 1990-10-30 JP JP2515465A patent/JPH04503077A/ja active Pending
- 1990-10-30 EP EP90916537A patent/EP0454813B1/de not_active Expired - Lifetime
- 1990-10-30 CA CA002044244A patent/CA2044244A1/en not_active Abandoned
- 1990-10-30 AT AT90916537T patent/ATE170754T1/de not_active IP Right Cessation
- 1990-10-30 ES ES90916537T patent/ES2121755T3/es not_active Expired - Lifetime
- 1990-10-30 DK DK90916537T patent/DK0454813T3/da active
- 1990-10-30 WO PCT/SE1990/000702 patent/WO1991006308A1/en not_active Ceased
- 1990-10-30 KR KR1019910700615A patent/KR920700678A/ko not_active Ceased
1991
- 1991-06-19 NO NO912391A patent/NO912391D0/no unknown
- 1991-06-28 FI FI913154A patent/FI102516B1/fi active
- 1991-06-28 RU SU914895868A patent/RU2035913C1/ru active

Also Published As

Publication number	Publication date
WO1991006308A1 (en)	1991-05-16
JPH04503077A (ja)	1992-06-04
DE69032646D1 (de)	1998-10-15
DE69032646T2 (de)	1999-05-27
CA2044244A1 (en)	1991-05-01
EP0454813A1 (de)	1991-11-06
DK0454813T3 (da)	1999-02-01
KR920700678A (ko)	1992-08-10
AU633647B2 (en)	1993-02-04
SE8903625D0 (sv)	1989-10-30
RU2035913C1 (ru)	1995-05-27
ATE170754T1 (de)	1998-09-15
AU6647090A (en)	1991-05-31
FI102516B (fi)	1998-12-31
NO912391L (no)	1991-06-19
ES2121755T3 (es)	1998-12-16
NO912391D0 (no)	1991-06-19
HU212935B (en)	1996-12-30
FI913154A0 (fi)	1991-06-28
SE8903625L (sv)	1991-05-01
FI102516B1 (fi)	1998-12-31
EP0454813B1 (de)	1998-09-09

Legal Events

Date

Code

Title

Description

1995-01-31

NAL

Patent in force

Ref document number: 8903625-5

Format of ref document f/p: F

2002-06-04

NUG

Patent has lapsed